Newton Fiona J, Burney Sue, Millar Jeremy L, Frydenberg Mark, Ng Kim T
School of Psychology, Psychiatry and Psychological Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia.
BJU Int. 2006 Jun;97(6):1179-83. doi: 10.1111/j.1464-410X.2006.06152.x.
To examine differences in sexual, urinary and bowel function, and bother, in patients with prostate cancer after treatment with radical prostatectomy (RP) or external beam radiation (EBRT), compared to a convenience sample of men with no diagnosis of prostate cancer, as little is known about the disease-specific health-related quality of life (HRQoL) of men in Australia after treatment for clinically localized prostate cancer.
The study was a retrospective cross-sectional survey of 95 controls, 82 men with localized prostate cancer treated with RP and 39 with EBRT at > or = 2 years before data were collected. Disease-specific HRQoL was assessed using the University of California Los Angeles Prostate Cancer Index, a validated measure that includes six subscales addressing sexual, urinary and bowel symptoms, and level of bother associated with the symptoms. Univariate analyses were conducted to ascertain differences in disease-specific HRQoL among the three groups. To minimize the influence of other factors, age and comorbid medical conditions were included as covariates.
Men treated with RP had more sexual and urinary symptoms (both P < 0.001) than those treated with EBRT, and more sexual bother (P < 0.001). Men treated with EBRT reported significantly worse bowel function (P = 0.02) and more bother (P < 0.001) with these symptoms than those who had RP.
Except for bowel dysfunction and the bother associated with these symptoms, disease-specific HRQoL was generally worse after RP than EBRT.
与未诊断为前列腺癌的便利样本男性相比,研究根治性前列腺切除术(RP)或外照射放疗(EBRT)治疗后前列腺癌患者的性功能、泌尿功能和肠道功能及困扰方面的差异,因为对于澳大利亚临床局限性前列腺癌治疗后男性特定疾病的健康相关生活质量(HRQoL)了解甚少。
该研究是一项回顾性横断面调查,在收集数据前≥2年,纳入95名对照、82名接受RP治疗的局限性前列腺癌男性患者和39名接受EBRT治疗的患者。使用加利福尼亚大学洛杉矶分校前列腺癌指数评估特定疾病的HRQoL,这是一项经过验证的测量工具,包括六个子量表,涉及性、泌尿和肠道症状以及与这些症状相关的困扰程度。进行单因素分析以确定三组之间特定疾病HRQoL的差异。为尽量减少其他因素的影响,将年龄和合并症作为协变量纳入。
接受RP治疗的男性比接受EBRT治疗的男性有更多的性和泌尿症状(均P<0.001),以及更多的性困扰(P<0.001)。与接受RP治疗的男性相比,接受EBRT治疗的男性报告肠道功能明显更差(P = 0.02),且这些症状带来的困扰更多(P<0.001)。
除肠道功能障碍及与之相关的困扰外,RP治疗后特定疾病的HRQoL总体上比EBRT治疗后更差。